BioNTech stock
BNTXNASDAQBioNTech SE, HealthcareISIN US09075V1026
36Score 36 out of 100, Weak
Price and trend
44 / 100
Price history
−24% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 11% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 42).
The price is 29% below its 52-week high. Largest decline in 7 years: 82% (August 2021 to August 2024).
Chart figures for advanced users
- SMA 50$93.42
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$95.89
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)42
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$83.89
- The lowest closing price of the last twelve months.
- Resistance$119.34
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BioNTech SE belongs to the Biotechnology industry (Germany) and, with a market value of $20.98B, is number 18 of 289 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $3.05B (up 0.2% year on year) and a loss of $1.21B.
Show more
- MEQIRI Score 36 out of 100 (Weak): rank 592 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 41.7% a year since 2020, Biotechnology median 19.4%.Growth 54
- More cash than debtCash $11.3B, financial debt $398.69M.Stability 60
Weaknesses
- Margin fallingOperating margin −22.6%, average of the prior years 18.1% (to 2024).Profitability 25
- Loss-makingLoss of $1.64B over the last 12 months.Fundamentals 20
- Turned to a lossEarnings per share from $0.07 in 2020 to −$5.00.Growth 54
The score is held back by fundamentals and capital allocation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 37 to 36.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue fell 15.1% on the same quarter a year earlier. Revenue has grown strongly since 2017, at around 61% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 78%, operating −23%, net −40%. Last 12 months: net −62%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 9 Mar 2027in 116 days
- Last reported
- 3 Nov 2026above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 4.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −5.74−4.9%
- Revenue
- $2.07B+3.4%
- Earnings per share
- −5.65−1.3%
- Revenue
- $2.07B+4.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −0.1%2026 revenue now EUR 1.6 to 1.9 billion and R&D EUR 2.0 to 2.3 billion with no clear direction given, and two trial milestones are now expected only in 2027.
“We now expect revenues in the range of EUR 1.6 billion to EUR 1.9 billion, adjusted R&D expenses in the range of EUR 2 billion to EUR 2.3 billion and adjusted SG&A expenses remaining unchanged in the range of EUR 700 million to EUR 800 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $84.23M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Sahin UgurSale
9 Oct 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 36,209
- Price
- $95.37
- Value
- $3.45M
- Sahin UgurSale
8 Oct 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 27,000
- Price
- $92.31
- Value
- $2.49M
- Sahin UgurSale
7 Oct 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 24,000
- Price
- $95.86
- Value
- $2.3M
Show 23 more
- Sahin UgurSale
6 Oct 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 21,000
- Price
- $96.81
- Value
- $2.03M
- Sahin UgurSale
5 Oct 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 72,000
- Price
- $97.23
- Value
- $7M
- Sahin UgurSale
2 Oct 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 17,000
- Price
- $96.72
- Value
- $1.64M
- Sahin UgurSale
1 Oct 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 17,000
- Price
- $97.46
- Value
- $1.66M
- Sahin UgurSale
30 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 32,000
- Price
- $98.12
- Value
- $3.14M
- Sahin UgurSale
29 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 34,000
- Price
- $98.26
- Value
- $3.34M
- Sahin UgurSale
28 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 34,000
- Price
- $98.47
- Value
- $3.35M
- Sahin UgurSale
25 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 27,000
- Price
- $98.69
- Value
- $2.66M
- Sahin UgurSale
24 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 39,000
- Price
- $98.99
- Value
- $3.86M
- Sahin UgurSale
23 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 30,000
- Price
- $99.40
- Value
- $2.98M
- Sahin UgurSale
22 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 46,000
- Price
- $100.72
- Value
- $4.63M
- Sahin UgurSale
21 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 33,000
- Price
- $97.81
- Value
- $3.23M
- Sahin UgurSale
18 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 30,000
- Price
- $96.22
- Value
- $2.89M
- Sahin UgurSale
17 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 34,000
- Price
- $98.60
- Value
- $3.35M
- Sahin UgurSale
16 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 15,000
- Price
- $96.09
- Value
- $1.44M
- Sahin UgurSale
15 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 34,000
- Price
- $96.49
- Value
- $3.28M
- Sahin UgurSale
14 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 41,000
- Price
- $99.45
- Value
- $4.08M
- Sahin UgurSale
11 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 45,000
- Price
- $96.93
- Value
- $4.36M
- Sahin UgurSale
10 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 20,500
- Price
- $96.31
- Value
- $1.97M
- Sahin UgurSale
9 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 36,000
- Price
- $97.78
- Value
- $3.52M
- Sahin UgurSale
8 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 37,000
- Price
- $99.20
- Value
- $3.67M
- Sahin UgurSale
4 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 31,500
- Price
- $103.52
- Value
- $3.26M
- Sahin UgurSale
3 Sept 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 45,000
- Price
- $102.85
- Value
- $4.63M
Shares and prices per ordinary share as filed with the SEC, not per depositary receipt.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at BioNTech
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- WuXi Biologics (Cayman)2269.HK $25.32B73
- United TherapeuticsUTHR $25.27B81
- IncyteINCY $24.81B70
- Alnylam PharmaceuticalsALNY $20.98B57
- Innovent Biologics1801.HK $19.28B61
- Ascendis PharmaASND $17.57B69
- ExelixisEXEL $17.55B90
- Neurocrine BiosciencesNBIX $17.15B77
ETFs that hold BioNTech
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 2.37% | 0.50% | €127.64M |
| Amundi F.A.Z. 100 UCITS ETFC006 | 0.92% | 0.15% | €104.39M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.66% | 0.35% | €1.25B |
Show 5 more
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 0.51% | 0.25% | €45.16M |
| Amundi S&P Eurozone Climate Paris Aligned UCITS ETF AccZPAB | 0.22% | 0.20% | €3.39B |
| Amundi Prime EurozonePR1Z | 0.14% | 0.05% | €1.15B |
| Xtrackers S&P Europe ex UK UCITS ETF 1DXUEK | 0.09% | 0.09% | €534.14M |
| L&G Europe ex UK Equity UCITS ETFETLN | 0.09% | 0.10% | €458.82M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 12 Sep 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.